Law.com Subscribers SAVE 30%

Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.

Medical Malpractice Law & StrategyKickerFeaturesTopicsLitigationSectionsNewsLJN Newsletters

Suits Against Generic Pharm Manufacturers

By Janice G. Inman
July 29, 2013

Among the landmark decisions issued by the U.S. Supreme Court in the final weeks of its last session, one that affects the nation's consumers of generic drugs got less attention than it might have deserved. In Mutual Pharmaceutical Co. Inc. v. Bartlett, 2013 U.S. LEXIS 4702 (U.S. 6/24/13), the court overturned the award of millions of dollars in damages to a woman injured by the use of a generic version of a patented, FDA-approved drug, after finding that the manufacturer could not be held responsible through a state-law claim for defective design, because it was actually a failure-to-warn claim in disguise.

Failure-to-warn claims against generic drug manufacturers, which by federal law are required to use the same warning labels used by manufacturers of their products' brand-name equivalents, have been precluded by the Supreme Court's 2011 decision in PLIVA Inc. v. Mensing, 131 S. Ct. 2567 (2011).

This premium content is locked for LJN Newsletters subscribers only

  • Stay current on the latest information, rulings, regulations, and trends
  • Includes practical, must-have information on copyrights, royalties, AI, and more
  • Tap into expert guidance from top entertainment lawyers and experts

For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473

Read These Next
The DOJ's Corporate Enforcement Policy: One Year Later Image

The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.

Use of Deferred Prosecution Agreements In White Collar Investigations Image

This article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.

The DOJ's New Parameters for Evaluating Corporate Compliance Programs Image

The parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.

Compliance Officers: Recent Regulatory Guidance and Enforcement Actions and Mitigating the Risk of Personal Liability Image

This article explores legal developments over the past year that may impact compliance officer personal liability.

Bankruptcy Sales: Finding a Diamond In the Rough Image

There is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.